Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 2/20 | 0.52 |
| ▸ | WNT3A | P56704 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.45 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19782935 | 0.85 | KMT2A (0.55) | CTNNB1WNT3AKMT2AALDH1A1MEN1 | |
| SCHEMBL15969141 | 0.80 | CTNNB1 (0.72) | CTNNB1WNT3AKMT2AALDH1A1MEN1 | |
| SCHEMBL18456830 | 0.79 | MAPT (0.64) | KMT2AALDH1A1MEN1PKMSMN1; SMN2 | |
| SCHEMBL1659363 | 0.78 | MAPT (0.71) | CTNNB1WNT3AKMT2AALDH1A1MEN1 | |
| SCHEMBL2848020 | 0.77 | KMT2A (0.61) | KMT2AALDH1A1MEN1SMN1; SMN2CYP1A2 | |
| SCHEMBL6568030 | 0.77 | TSHR (0.73) | KMT2AMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18662463 | 0.74 | MEN1 (0.47) | CTNNB1WNT3AKMT2AALDH1A1MEN1 | |
| SCHEMBL29668496 | 0.74 | MEN1 (0.71) | CTNNB1WNT3AKMT2AALDH1A1MEN1 | |
| SCHEMBL28881824 | 0.74 | MEN1 (0.71) | CTNNB1WNT3AKMT2AALDH1A1MEN1 | |
| SCHEMBL6280969 | 0.73 | PDE4D (0.60) | CTNNB1WNT3AKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2020-06-11 | — | — | US | disclosed |
| WO-2018011376-A1 | PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CCL5, CXCR3, CXCL10 | CTNNB1 1144/4885WNT3A 3288/4885KMT2A 4043/4885 |
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CCL5, CXCR3, CXCL10 | CTNNB1 1144/4885WNT3A 3288/4885KMT2A 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.